7,021,277 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • May 9th, 2011 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
Keryx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”) for whom Stifel, Nicolaus & Company, Incorporated is acting as representative (the “Representative”), an aggregate of 7,021,277 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”).
